P/E ratio for Sangamo Therapeutics (SGMO)

P/E ratio history for Sangamo Therapeutics from 2001 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Gilead Sciences GILD	20.4	-1,580.38%	🇺🇸 USA
Alnylam Pharmaceuticals ALNY	-60.6	4,298.16%	🇺🇸 USA
Amgen AMGN	20.5	-1,586.42%	🇺🇸 USA
Biogen BIIB	8.59	-723.35%	🇺🇸 USA
Dow DOW	24.4	-1,870.83%	🇺🇸 USA
Johnson & Johnson JNJ	11.0	-900.85%	🇺🇸 USA
BioMarin Pharmaceutical BMRN	81.2	-5,990.38%	🇺🇸 USA
Merck MRK	54.3	-4,040.25%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.